AXIM Biotechnologies, Inc. (AXIM)
OTCMKTS: AXIM · Delayed Price · USD
0.0150
+0.0002 (1.35%)
May 1, 2024, 10:23 AM EDT - Market open
AXIM Biotechnologies Revenue
In the year 2023, AXIM Biotechnologies had annual revenue of $39.52K with 345.27% growth. Revenue in the quarter ending December 31, 2023 was $12.86K with 70.07% year-over-year growth.
Revenue (ttm)
$39.77K
Revenue Growth
+348.07%
P/S Ratio
105.03
Revenue / Employee
$6,628
Employees
6
Market Cap
4.18M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 39.52K | 30.64K | 345.27% |
Dec 31, 2022 | 8.88K | -51.59K | -85.32% |
Dec 31, 2021 | 60.46K | - | - |
Dec 31, 2020 | 0 | - | - |
Dec 31, 2019 | 799.48K | 603.87K | 308.70% |
Dec 31, 2018 | 195.61K | 148.04K | 311.19% |
Dec 31, 2017 | 47.57K | 514.00 | 1.09% |
Dec 31, 2016 | 47.06K | -2.08K | -4.23% |
Dec 31, 2015 | 49.14K | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 21.67K | -21.67K | -50.00% |
Dec 31, 2012 | 43.33K | 33.33K | 333.33% |
Dec 31, 2011 | 10.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 371.62B |
Johnson & Johnson | 85.16B |
Merck & Co. | 60.12B |
AbbVie | 54.32B |
Novartis AG | 49.92B |
AstraZeneca | 47.61B |
Thermo Fisher | 42.86B |
Abbott Laboratories | 40.11B |
AXIM News
- 5 weeks ago - VIDEO: AXIM Biotechnologies CEO Presents at Benzinga Virtual Healthcare Summit 2024 - GlobeNewsWire
- 2 months ago - AXIM® Biotechnologies' Tear Based Testing Platform Continues to Gain Traction After Successful Clinical Validation - GlobeNewsWire
- 4 months ago - AXIM® Biotechnologies Partners With Leading Diagnostic Manufacturer Auer Precision to Scale Assay Production - GlobeNewsWire
- 8 months ago - AXIM® Biotechnologies Develops First Non-Invasive, Rapid, Point-of-Care, Diagnostic Test for Parkinson's Disease - Business Wire
- 9 months ago - AXIM® Biotechnologies Receives Notice of U.S. Patent Allowance for Three Separate Patents Including Its Rapid Point of Care Neutralizing Antibody Test - Business Wire
- 10 months ago - Update: AXIM® Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers Nationwide - GlobeNewsWire
- 10 months ago - AXIM® Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers Nationwide - GlobeNewsWire
- 1 year ago - AXIM Biotechnologies Announces Over 40 Initial Clinic Commitments for Its Full Diagnostic Assay Platform Launch - GlobeNewsWire